1-(顺-9-十八碳烯基)-2-乙酰基-sn-甘油2-乙酰基-1-油酰基-sn-甘油 | 86390-77-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 1-(顺-9-十八碳烯基)-2-乙酰基-sn-甘油2-乙酰基-1-油酰基-sn-甘油
• 中文别名: 1-油酰基-2-乙酰基-sn-丙三醇；2-乙酰基-1-油酰基-SN-丙三醇；1-(顺-9-十八碳烯基)-2-乙酰基-sn-甘油；2-乙酰基-1-油酰基-sn-甘油
• 英文名称: 1-Oleoyl-2-acetyl-sn-glycerol
• 英文别名: [(2S)-2-acetyloxy-3-hydroxypropyl] (Z)-octadec-9-enoate
• CAS: 86390-77-4
• 化学式: C₂₃H₄₂O₅
• 分子量: 398.6
• InChiKey: PWTCCMJTPHCGMS-YRBAHSOBSA-N

物化性质

• 沸点：
  490.0±15.0 °C(Predicted)
• 密度：
  0.980±0.06 g/cm3(Predicted)
• 溶解度：
  乙醇：20 mg/mL
• 稳定性/保质期：
  按规定使用和贮存时不会分解，并应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  28
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• WGK Germany：
  3

文献信息

• [EN] INHIBITORS OF TRPC6<br/>[FR] INHIBITEURS DE TRPC6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019158572A1

  公开（公告）日：2019-08-22

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药用盐，其中R1至R6，A，U，V，W，X，Y和Z如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• [EN] OXIME COMPOUNDS USEFUL AS T CELL ACTIVATORS<br/>[FR] COMPOSÉS OXIME UTILES COMME ACTIVATEURS DE LYMPHOCYTES T
  申请人：GOSSAMER BIO SERVICES INC

  公开号：WO2021258010A1

  公开（公告）日：2021-12-23

  Disclosed herein are oxime compounds having the structure of Formula (I):or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein R1, R2, R3, a, L, X, and Y are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  本文披露了具有Formula (I)结构的肟化合物：或其药用可接受的盐、溶剂化合物、水合物、异构体、互变异构体、拉氏体、或同位素，其中R1、R2、R3、a、L、X和Y如本文所定义。还提供了包括它们的药物组合物、制备它们的方法以及用途，用于治疗或预防疾病、紊乱和状况。这些化合物是二酰甘油激酶α(DGKα)和二酰甘油激酶ζ(DGKζ)的抑制剂，并且在治疗与DGKα和/或DGKζ活性相关的疾病、紊乱和状况方面是有用的。特别地，这些化合物对于治疗病毒感染和增生性疾病，如癌症，是有用的。
• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• Reagents and methods for cancer treatment and prevention
  申请人：Niazi R. Kayvan

  公开号：US20070224207A1

  公开（公告）日：2007-09-27

  The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.

  本发明通常涉及预防和/或治疗癌症，更具体地涉及治疗肿瘤，包括实体肿瘤及其转移，而不使用放射线或标准化疗药物。在一种实施方式中，本发明涉及一种方法，包括：a）提供肿瘤细胞给一个受试者，b）从该受试者中去除至少一部分肿瘤细胞以创建去除的细胞，c）使用刺激剂，包括沙环菜素和/或沙环菜素相关化合物，处理至少一部分所去除的细胞外体，以创建处理后的肿瘤细胞；以及d）将所处理的肿瘤细胞（或其碎片）在体内重新引入同一受试者，以产生抗癌治疗效果。
• Protein phosphatase inhibitors for use in therapy
  申请人：NATIONAL UNIVERSITY OF SINGAPORE

  公开号：EP0551200A1

  公开（公告）日：1993-07-14

  Protein phosphatase inhibitors such as okadaic acid, a phosphatase inhibitor dervied from a marine black sponge, and calyculin A are able to mimic tumor necrosis factor or interleukin-1. These phosphatase inhibitors may therefore be used to treat conditions which are treatable by tumor necrosis factor or interleukin-1 such as an advanced cancer or a leukaemia.

  蛋白磷酸酶抑制剂，如 okadaic 酸（一种从海洋黑海绵中提取的磷酸酶抑制剂）和钙霉素 A 能够模拟肿瘤坏死因子或白细胞介素-1。因此，这些磷酸酶抑制剂可用于治疗肿瘤坏死因子或白介素-1 可治疗的疾病，如晚期癌症或白血病。